Is Mira applicable to post-menopausal women at all?Updated a month ago

Yes. In postmenopausal individuals, estrogen and progesterone are typically low and stable, but FSH often remains elevated and variable. Routine cycle tracking has limited utility here, but tracking FSH remains a clinically meaningful biomarker, as persistently elevated FSH has been associated with multiple long-term health risks.

You can find the full guide to using Mira in perimenopause and menopause here.

For patients using hormone replacement therapy (HRT), FSH tracking provides an important way to assess treatment effectiveness. While Mira E3G values alone are not sufficient to determine whether estrogen therapy is therapeutic, serial FSH monitoring—interpreted alongside E3G trends and patient-reported symptom response—can indicate whether estrogen is being absorbed and exerting appropriate physiologic feedback.

Mira is most clinically useful when these measures are evaluated together. Suppression or stabilization of FSH over time, combined with symptom improvement, offers a practical approach to evaluating HRT response and potential risk reduction—insight that serum E2 or urinary E3G values alone cannot provide. This makes ongoing Mira monitoring a valuable tool in both perimenopause and postmenopause.